A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging

被引:42
作者
Linders, Annet Nicole [1 ]
Dias, Itamar Braga [1 ]
Lopez Fernandez, Teresa [2 ]
Tocchetti, Carlo Gabriele [3 ,4 ,5 ,6 ]
Bomer, Nils [1 ]
van der Meer, Peter [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1,POB 30-001, Groningen, Netherlands
[2] La Paz Univ Hosp, IdiPAZ Res Inst, Div Cardiol, Cardiac Imaging & Cardiooncol Unit, Madrid, Spain
[3] Univ Naples Federico II, Dept Translat Med Sci DISMET, Naples, Italy
[4] Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, Naples, Italy
[5] Univ Naples Federico II, Interdept Ctr Clin & Translat Sci CIRCET, Naples, Italy
[6] Univ Naples Federico II, Interdept Hypertens Res Ctr CIRIAPA, Naples, Italy
来源
NPJ AGING | 2024年 / 10卷 / 01期
基金
欧洲研究理事会;
关键词
INDUCED CARDIAC-HYPERTROPHY; BREAST-CANCER; SENESCENT CELLS; CELLULAR SENESCENCE; OXIDATIVE STRESS; INDUCED CARDIOMYOPATHY; RANDOMIZED-TRIALS; TOPOISOMERASE-II; DNA; HEART;
D O I
10.1038/s41514-024-00135-7
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The population of cancer survivors is rapidly increasing due to improving healthcare. However, cancer therapies often have long-term side effects. One example is cancer therapy-related cardiac dysfunction (CTRCD) caused by doxorubicin: up to 9% of the cancer patients treated with this drug develop heart failure at a later stage. In recent years, doxorubicin-induced cardiotoxicity has been associated with an accelerated aging phenotype and cellular senescence in the heart. In this review we explain the evidence of an accelerated aging phenotype in the doxorubicin-treated heart by comparing it to healthy aged hearts, and shed light on treatment strategies that are proposed in pre-clinical settings. We will discuss the accelerated aging phenotype and the impact it could have in the clinic and future research.
引用
收藏
页数:9
相关论文
共 186 条
[1]   In vitro aged, hiPSC-origin engineered heart tissue models with age-dependent functional deterioration to study myocardial infarction [J].
Acun, Aylin ;
Trung Dung Nguyen ;
Zorlutuna, Pinar .
ACTA BIOMATERIALIA, 2019, 94 :372-391
[2]   Cardiac Troponins are Among Targets of Doxorubicin-Induced Cardiotoxicity in hiPCS-CMs [J].
Adamcova, Michaela ;
Skarkova, Veronika ;
Seifertova, Jitka ;
Rudolf, Emil .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)
[3]   Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: Structural features and biological implications [J].
Agudelo, Daniel ;
Bourassa, Philippe ;
Berube, Gervais ;
Tajmir-Riahi, Heidar-Ali .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2014, 66 :144-150
[4]   IMPACT OF DOXORUBICIN ON SURVIVAL IN ADVANCED OVARIAN-CANCER [J].
AHERN, RP ;
GORE, ME .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :726-732
[5]  
Ahrenkilde Hansen P., 2022, A cancer plan for Europe
[6]   The molecular hallmarks of epigenetic control [J].
Allis, C. David ;
Jenuwein, Thomas .
NATURE REVIEWS GENETICS, 2016, 17 (08) :487-500
[7]   Subcellular metabolite profiles of the parent CCRF-CEM and the derived CEM/C2 cell lines after treatment with doxorubicin [J].
Anderson, AB ;
Arriaga, EA .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 808 (02) :295-302
[8]   Length-independent telomere damage drives post-mitotic cardiomyocyte senescence [J].
Anderson, Rhys ;
Lagnado, Anthony ;
Maggiorani, Damien ;
Walaszczyk, Anna ;
Dookun, Emily ;
Chapman, James ;
Birch, Jodie ;
Salmonowicz, Hanna ;
Ogrodnik, Mikolaj ;
Jurk, Diana ;
Proctor, Carole ;
Correia-Melo, Clara ;
Victorelli, Stella ;
Fielder, Edward ;
Berlinguer-Palmini, Rolando ;
Owens, Andrew ;
Greaves, Laura C. ;
Kolsky, Kathy L. ;
Parini, Angelo ;
Douin-Echinard, Victorine ;
Lebrasseur, Nathan K. ;
Arthur, Helen M. ;
Tual-Chalot, Simon ;
Schafer, Marissa J. ;
Roos, Carolyn M. ;
Miller, Jordan D. ;
Robertson, Neil ;
Mann, Jelena ;
Adams, Peter D. ;
Tchkonia, Tamara ;
Kirkland, James L. ;
Mialet-Perez, Jeanne ;
Richardson, Gavin D. ;
Passos, Joao F. .
EMBO JOURNAL, 2019, 38 (05)
[9]   Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent [J].
Anuar, Nur Najmi Mohamad ;
Hisam, Nur Syahidah Nor ;
Liew, Sze Ling ;
Ugusman, Azizah .
FRONTIERS IN PHARMACOLOGY, 2020, 11
[10]   How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? [J].
Aubrey, Brandon J. ;
Kelly, Gemma L. ;
Janic, Ana ;
Herold, Marco J. ;
Strasser, Andreas .
CELL DEATH AND DIFFERENTIATION, 2018, 25 (01) :104-113